In our study, we wanted to assess the therapeutic potential of WT GW3965‐treated EOCs and their secretome on the development of atherosclerosis using the atherogenic Ldlr‐knockout (Ldlr−/−) mouse model (Figure 3A). This evidence concerns the gene LDLR and atherosclerosis.